Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bevacizumab + Chemo in Resectable NSCLC
NCT00025389Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Nov 2001
- Primary completion
- Dec 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by University of Chicago. Primary endpoint: Clinical Complete and Partial Response Rate. Started Nov 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00025389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025389.